File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1158/0008-5472.CAN-18-3837
- Scopus: eid_2-s2.0-85064217497
- PMID: 30760520
- WOS: WOS:000463005700039
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Transcriptomics associates molecular features with 18F-fluorocholine PET/CT imaging phenotype and its potential relationship to survival in hepatocellular carcinoma
Title | Transcriptomics associates molecular features with <sup>18</sup>F-fluorocholine PET/CT imaging phenotype and its potential relationship to survival in hepatocellular carcinoma |
---|---|
Authors | |
Issue Date | 2019 |
Citation | Cancer Research, 2019, v. 79, n. 7, p. 1696-1704 How to Cite? |
Abstract | Studies involving transcriptomics have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) has also identified distinct molecular imaging subtypes, including those with increased and decreased choline metabolism as measured by the tissue uptake of the radiopharmaceutical 18F-fluorocholine. Gene signatures reflecting the molecular heterogeneity of HCC may identify the biological and clinical significance of these imaging subtypes. In this study, 41 patients underwent 18F-fluorocholine PET/CT, followed by tumor resection and gene expression profiling. Over- and underexpressed components of previously published gene signatures were evaluated for enrichment between tumors with high and low 18F-fluorocholine uptake using gene set analysis. Significant gene sets were enumerated by FDR based on phenotype permutation. Associations with overall survival were analyzed by univariate and multivariate proportional hazards regression. Ten gene sets related to HCC were significantly associated with high tumor 18F-fluorocholine uptake at FDR q < 0.05, including those from three different clinical molecular classification systems and two prognostic signatures for HCC that showed predictive value in the study cohort. Tumor avidity for 18F-fluorocholine was associated with favorable characteristics based on these signatures with lower mortality based on survival analysis (HR 0.36; 95% confidence interval, 0.14-0.95). Tumors demonstrating high 18F-fluorocholine uptake were also enriched for genes involved in oxidative phosphorylation, fatty acid metabolism, peroxisome, bile acid metabolism, xenobiotic metabolism, and adipogenesis. These results provide a pathobiological framework to further evaluate 18F-fluorocholine PET/CT as a molecular and prognostic classifier in HCC. Significance: A pathobiological framework for HCC brings together multiple prognostically relevant gene signatures via convergence with 18F-fluorocholine PET/CT imaging phenotype. |
Persistent Identifier | http://hdl.handle.net/10722/342240 |
ISSN | 2023 Impact Factor: 12.5 2023 SCImago Journal Rankings: 3.468 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwee, Sandi A. | - |
dc.contributor.author | Tiirikainen, Maarit | - |
dc.contributor.author | Sato, Miles M. | - |
dc.contributor.author | Acoba, Jared D. | - |
dc.contributor.author | Wei, Runmin | - |
dc.contributor.author | Jia, Wei | - |
dc.contributor.author | Le Marchand, Loic | - |
dc.contributor.author | Wong, Linda L. | - |
dc.date.accessioned | 2024-04-17T07:02:22Z | - |
dc.date.available | 2024-04-17T07:02:22Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Cancer Research, 2019, v. 79, n. 7, p. 1696-1704 | - |
dc.identifier.issn | 0008-5472 | - |
dc.identifier.uri | http://hdl.handle.net/10722/342240 | - |
dc.description.abstract | Studies involving transcriptomics have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) has also identified distinct molecular imaging subtypes, including those with increased and decreased choline metabolism as measured by the tissue uptake of the radiopharmaceutical 18F-fluorocholine. Gene signatures reflecting the molecular heterogeneity of HCC may identify the biological and clinical significance of these imaging subtypes. In this study, 41 patients underwent 18F-fluorocholine PET/CT, followed by tumor resection and gene expression profiling. Over- and underexpressed components of previously published gene signatures were evaluated for enrichment between tumors with high and low 18F-fluorocholine uptake using gene set analysis. Significant gene sets were enumerated by FDR based on phenotype permutation. Associations with overall survival were analyzed by univariate and multivariate proportional hazards regression. Ten gene sets related to HCC were significantly associated with high tumor 18F-fluorocholine uptake at FDR q < 0.05, including those from three different clinical molecular classification systems and two prognostic signatures for HCC that showed predictive value in the study cohort. Tumor avidity for 18F-fluorocholine was associated with favorable characteristics based on these signatures with lower mortality based on survival analysis (HR 0.36; 95% confidence interval, 0.14-0.95). Tumors demonstrating high 18F-fluorocholine uptake were also enriched for genes involved in oxidative phosphorylation, fatty acid metabolism, peroxisome, bile acid metabolism, xenobiotic metabolism, and adipogenesis. These results provide a pathobiological framework to further evaluate 18F-fluorocholine PET/CT as a molecular and prognostic classifier in HCC. Significance: A pathobiological framework for HCC brings together multiple prognostically relevant gene signatures via convergence with 18F-fluorocholine PET/CT imaging phenotype. | - |
dc.language | eng | - |
dc.relation.ispartof | Cancer Research | - |
dc.title | Transcriptomics associates molecular features with <sup>18</sup>F-fluorocholine PET/CT imaging phenotype and its potential relationship to survival in hepatocellular carcinoma | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1158/0008-5472.CAN-18-3837 | - |
dc.identifier.pmid | 30760520 | - |
dc.identifier.scopus | eid_2-s2.0-85064217497 | - |
dc.identifier.volume | 79 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 1696 | - |
dc.identifier.epage | 1704 | - |
dc.identifier.eissn | 1538-7445 | - |
dc.identifier.isi | WOS:000463005700039 | - |